

Ajanta House, Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com

6th October, 2017

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Dear Sir,

Scrip Code: BSE - AJANTPHARM 532331/ NSE - AJANTPHARM EQ

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find:

1. Quarterly Compliance Report on Corporate Governance (CG) for the quarter ended on $30^{\rm th}$ September, 2017; and

2. CG report for the half year ended 30th September 2017, in the prescribed format.

Thanking You,

Yours faithfully, for AJANTA PHARMA LIMITED

GAURANG SHAH AVP - Legal & Company Secretary

M

Encl.: a/a

1. Name of Listed Entity : Ajanta Pharma Limited

2. Half year ending : 30th September, 2017

Format to be submitted by listed entity at the end of 6 months after end of financial year along-with second quarter report of next financial

l Affirmations		
Broad heading	Regulation Number	Compliance status (Yes/No/NA)refer note below
Copy of the annual report including balance	46(2)	Yes
sheet, profit and loss account, directors		
report, corporate governance report, business		
responsibility report displayed on website		
Presence of Chairperson of Audit Committee	18(1)(d)	Yes
at the Annual General Meeting		
Presence of Chairperson of the nomination 19(3)	19(3)	Yes
and remuneration committee at the annual		
general meeting		
Whether "Corporate Governance Report" 34(3) read with para C of	34(3) read with para C of	Yes
disclosed in Annual Report	Schedule V	
Note		

1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2 If status is "No" details of non-compliance may be given here.

3 If the Listed Entity would like to provide any other information the same may be indicated here.

Name & Designation: Mr. Gaurang Shah

Company Secretary / Compliance Officer / Managing Director / CEO: Company Secretary & Compliance Officer

For AJANTA PHARMA LIMITED

GAURANG SHAH

AVP - Legal & Company Secretary

Name of Listed Entity : Ajanta Pharma Limited
 Quarter ending : 30th September, 2017

			ARTER"	"SAME AS PREVIOUS QUARTER"	"SAME			
Z Christian I							Composition of Committees	II. Com
					ompanies also	anship of unlisted c	* Includes membership/chairmanship of unlisted companies also	* inclu
HARIN	SRC - 1		years		7	06896404		
Name	Audit - 7 (*)	One	year s	01.04.2014	Independent	AFNPG6211K &	Anjana Grewal	Ms.
Of 2 Audit		Two	5	01.04.2014	Independent	ADKPD7258G & 00544948	Prabhakar Dalal	Mr.
			years		-	06563472	-	:
None	Audit - 1	One	5	01.04.2014	Independent	ALJPK1873B &	K H Viswanathan	۸r.
- 9	SRC - 1		years		-	00208833		
Of 1 SRC	Audit - None	One	5	01.04.2014	Independent	AABPC8668D &	Anil Kumar	<u>γ</u>
mmittee	SRC - None		years			00234118	Khetan	
Of 1 Audit	Audit - 1	Two	5	01.04.2014	Independent	AAHPK5606M &	Chandrakant	Ă
NOTICE	SRC - 1	Ċ	5	01.00.10	- According	00302467	1 m) con m n n n n n n n n	
Non	Audit - None	One	NA	01 05 2013	Executive	AACPA2797D &	Rajesh M. Agrawal	Mr
None	None	One	NA	01.04.2013	Executive	AACPA2793C & 00073673	Yogesh M. Agrawal	۸r.
							Agrawal	
None	None	One	X	01.04.2015	Executive	AAHPA8178J &	Madhusudan B.	۸r.
						00073680	Agrawal	
None	None	One	N	01.04.2013	Executive	AACPA3161C &	Purushottam B.	Mr.
None	Audit - 1 SRC - None	One	¥	N A	Chairperson	AACPA2742D & 00073828	Mannalal B. Agrawal	Mr.
		Regulations)						
		JQ.						2
Listing Regulations)	בוזרווא ועכאמענוטווז)	25(1) of						
entity (Refer	Regulation 26(1) of listing Regulations	(Reter			Nominee) ^{&}			
including this listed	entity (Refer	listed entity			independent			
listed entities	including this listed	including this		/cessation	Executive/			
Committee held in	Committee(s)	entities		term	Non-			
ehold	Audit/ Stakeholder	in listed		in the current	/Executive/			Ms.)
airperson	rships	Directorship	гe	Appointment	(Chairperson	& DIN		(Mr./
No of post of	Number of	No of	Tenu	Date of	Category	PAN\$	Name of the Director	Title
						ectors	l. Composition of Board of Directors	I. Com

III. Meeting of Board of Directors			
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the		Maximum gap between any two consecutive (in number of
	relevant quarter	days)	
3 rd May, 2017	9 th August, 2017	97 (excluding meeting days)	neeting days)
IV. Meeting of Committees	The state of the s		
Date(s) of meeting of the committee in the	Whether requirement of	Date(s) of meeting of	Maximum gap between any two
relevant quarter		the committee in the	ve meetings in number of da
The first of the f		previous quarter	
Audit Committee:	Yes, all the Committee 3	3 rd May, 2017	97 (excluding meeting days)
9 th August, 2017	members were present		
Stakeholders' Relationship Committee:	Yes, all the Committee 3	3 rd May, 2017	97 (excluding meeting days)
9 th August, 2017		;	0 - 3 - 3
V. Related Party Transactions			
Subject		Compliance stat	Compliance status (Yes/No/NA)refer note below
Whether prior approval of audit committee obtained		Yes	
Whether shareholder approval obtained for material RPT	RPT	NA	1974
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by	nibus approval have been reviev	wed by Yes	
Audit Committee			
VI. Affirmations			THE PARTY OF THE P
The annualities of Decade (5.7)			

- The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The composition of the following committees is in terms of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015
- Audit Committee
- Nomination & Remuneration committee
- c. Stakeholders relationship committee
- requirements) Regulations, 2015. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure
- disclosure requirements) Regulations, 2015. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and
- 5. This report will be placed before Board of Directors at the ensuing Board meeting.

 Name & Designation: Gaurana C. Shah

Name & Designation: Gaurang C. Shah

Company Secretary / Compliance Officer / Managing Director / CEO: Company Secretary & Compliance Officer

For AJANTA PHARMA LIMITED

GAURANG SHAH

AVP - Legal & Company Secretary

